Evidence map›Paper›PMID 38523540›Full record

ArticleCurrent computer-aided drug design2025

Repurposing of Compounds from

Narjes Noori Goodarzi, Behzad Shahbazi, Elham Haj Agha Gholizadeh Khiavi, Mahshid Khazani Asforooshani, Sahar Abed, Farzad Badmasti

Abstract read
PubMed Publisher
In one paragraph

Article in Current computer-aided drug design, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact, top 96% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 0 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 1 country.

Narjes Noori GoodarziDepartment of Pathobiology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.
Behzad ShahbaziSchool of Pharmacy, Semnan University of Medical Sciences, Semnan, Iran.
Elham Haj Agha Gholizadeh KhiaviDepartment of Bacteriology, Pasteur Institute of Iran, Tehran, Iran.
Mahshid Khazani AsforooshaniDepartment of Microbiology, Faculty of Biological Sciences, Alzahra University, Tehran, Iran.
Sahar AbedDepartment of Microbial Biotechnology, Faculty of Basic Sciences and Advanced Technologies in Biology, University of Science and Culture, Tehran, Iran.
Farzad BadmastiDepartment of Bacteriology, Pasteur Institute of Iran, Tehran, Iran.
Pasteur Institute of Iran · IRAlzahra University · IRSemnan University of Medical Sciences · IRUniversity of Science and Culture · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDrug-resistant

resultsSix H-donor conserved residues were selected as protein active sites, including Arg- 220, Tyr-38, Gln-154, Asn-73, Arg-74, and Thr-24. Through virtual screening, a total of nine compounds with the highest binding affinity to the FemA protein were identified. Frigocyclinone and C

conclusionOur findings suggest that Frigocyclinone and C

Indexed as

AminoacyltransferasesAnti-Bacterial AgentsBacterial ProteinsDrug RepositioningEnzyme InhibitorsStaphylococcus aureusStreptomycesDrug Resistance, BacterialLigandsMolecular Docking SimulationMolecular Dynamics SimulationAminoacyltransferasesAnti-Bacterial AgentsBacterial ProteinsEnzyme InhibitorsLigandsdrug discoverydrug repurposing.FemAmolecular dynamicsStaphylococcus aureusstructure-based virtual screening

Identifiers

PMID38523540
OpenAlexW4393156061

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.